Tri Locum Partners LP 13F holdings, Q4 2025
Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →
Tri Locum Partners LP disclosed 15 US equity positions worth $770.1m in its Q4 2025 13F filing. The largest position was JNJ at 16.2% of the reported book, followed by DHR and LLY. Against the Q3 2025 filing, it opened 7 new positions, added to 4 and reduced 4 among the top 15 holdings.
What did Tri Locum Partners LP own in Q4 2025? Top 15 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2025 |
|---|---|---|---|---|---|---|---|
| 1 | JNJ JOHNSON & JOHNSON | Healthcare | 16.2% | $124.8m | 603,143 | 99% | added |
| 2 | DHR DANAHER CORPORATION | Healthcare | 10.3% | $79.4m | 346,875 | – | new |
| 3 | LLY ELI LILLY & CO | Healthcare | 8.8% | $68.0m | 63,284 | – | new |
| 4 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 7.7% | $58.9m | 120,921 | -1% | reduced |
| 5 | ASND ASCENDIS PHARMA A/S | Healthcare | 7.3% | $56.5m | 265,015 | 52% | added |
| 6 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 6.5% | $50.1m | 86,023 | 27% | added |
| 7 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 6.4% | $49.6m | 520,508 | – | new |
| 8 | TEVA TEVA PHARMACEUTICAL INDS LTD | Healthcare | 5.8% | $44.8m | 1,435,865 | – | new |
| 9 | IONS IONIS PHARMACEUTICALS INC | Healthcare | 5.7% | $44.1m | 557,174 | – | new |
| 10 | VERA VERA THERAPEUTICS INC | Healthcare | 5.3% | $40.8m | 805,689 | -32% | reduced |
| 11 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 4.8% | $36.8m | 201,627 | -31% | reduced |
| 12 | ARGX ARGENX SE | Healthcare | 4.1% | $31.7m | 37,653 | -13% | reduced |
| 13 | NUVALENT INC | 4.0% | $30.9m | 307,371 | – | new | |
| 14 | DXCM DEXCOM INC | Healthcare | 3.6% | $28.0m | 421,600 | – | new |
| 15 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 3.3% | $25.6m | 622,403 | 240% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.